Evidence map›Paper›PMID 42531680›Full record

ArticleMultiple sclerosis and related disorders2026

OCT-defined optic atrophy thresholds are associated with blunted optic nerve swelling in recurrent optic neuritis.

Stephanie B Syc-Mazurek, Delaney Liskey, Deena A Tajfirouz, Kevin D Chodnicki, Shahriyar Majidi, Zachary Duvigneaud, Sarah Demortiere, Natacha Stolowy, Amy Kunchok, Larry P Frohman and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Multiple sclerosis and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Stephanie B Syc-MazurekDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Delaney LiskeyRegenerative Sciences Ph.D. Program, Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Jacksonville, FL, USA.
Deena A TajfirouzDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Kevin D ChodnickiDepartment of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Shahriyar MajidiDivision of Neuro-Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Zachary DuvigneaudHospices Civils de Lyon, Service de neurocognition et neuro-ophtalmologie, Université Claude Bernard Lyon 1, Lyon, France.
Sarah DemortiereDepartment of Neurology, Assistance Publique - Hôpitaux de Marseille, France.
Natacha StolowyDepartment of Ophthalmology, University Hospital of Marseille, Marseille, France; Assistance Publique Hôpitaux de Marseille, Aix Marseille Univ, Hôpital de la Timone, Pôle d'Imagerie, CEMEREM, Marseille, France.
Amy KunchokMellen Center for Multiple Sclerosis, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA.
Larry P FrohmanDepartment of Ophthalmology, Rutgers Rutgers-New Jersey Medical School, NJ, USA.
Hadas Stiebel-KalishDepartment of Ophthalmology, Rabin Medical Center and Eye Laboratory at Felsenstein Medical Research Center, Gray Faculty of Medicine & Health Sciences, Tel Aviv University, Israel.
Rita ZlatkinDepartment of Ophthalmology, Rabin Medical Center and Eye Laboratory at Felsenstein Medical Research Center, Gray Faculty of Medicine & Health Sciences, Tel Aviv University, Israel.
Tanyatuth PadungkiatsagulDepartment of Ophthalmology, Mahidol University, Bangkok, Thailand.
Ilya AyzenbergDepartment of Neurology, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
Bertrand AudoinDepartment of Neurology, Assistance Publique - Hôpitaux de Marseille, France; Assistance Publique - Hôpitaux de Marseille, France, Center for Magnetic Resonance in Biology and Medicine (CRMBM), Aix-Marseille University, France.
Amanda D HendersonDivision of Neuro-Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Romain MarignierService de Neurologie, sclérose en plaques, pathologies de la myéline et neuroinflammation, Hôpital Neurologique P. Wertheimer, Hospices Civils de Lyon, France.
Caroline Froment TiliketeHospices Civils de Lyon, Service de neurocognition et neuro-ophtalmologie, Université Claude Bernard Lyon 1, Lyon, France.
Elias S SotirchosDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sean J PittockDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.
Eoin P FlanaganDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA.
John J ChenDepartment of Neurology and Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Ophthalmology, Mayo Clinic College of Medicine, Rochester, MN, USA. Electronic address: chen.john@mayo.edu.

Funding

Utilizing epidemiology, imaging and fluid biomarkers in MOG antibody-associated disease to inform prognosis, pathogenesis and therapeuticsR01NS113828 · NINDS · MAYO CLINIC ROCHESTER · PI Eoin P Flanagan · 2020 to 2026
$2.4M
NINDS NIH HHS R01 NS113828
6 · The paper itself

Abstract

backgroundAcute optic neuritis (ON) can be associated with optic disc edema which can be quantified by optical coherence tomography (OCT) peripapillary retinal nerve fiber layer (RNFL) measurements. In patients with recurrent visual symptoms, objective measures can confirm a new clinical attack. Optic atrophy may preclude RNFL swelling during recurrent ON, but this has not been systematically evaluated.

methodsPatients with recurrent ipsilateral ON with OCT within 2 weeks of symptoms were retrospectively identified from 8 international centers.

resultsWe identified 112 patients (MOGAD, 45[40%]; MS, 36[32%], NMOSD, 20[18%], idiopathic ON, 11[10%]) with 137 episodes of recurrent ON (median age, 39 years [range 12-78]; female sex, 81 [72%]). Of patients with macular ganglion cell-inner plexiform layer (GCIPL) measures during acute recurrent ON, those with preserved GCIPL (≥65 μm, n=36) showed greater RNFL thickness (mean 108 μm [65-368], p<0.0001) than those with thin GCIPL (<65μm, n=30; mean 65μm [50-84]). Higher RNFL thickness measurements, which can be consistent with RNFL swelling, (≥15 µm above GCIPL) occurred in 21/36 (58%) patients with GCIPL ≥65 µm vs 5/30 (17%) patients with GCIPL <65µm (p<0.001).

conclusionsPatients with severe optic atrophy may have limited optic nerve swelling during acute ON. Ganglion cell layer thickness can serve as a surrogate marker for optic atrophy during early acute ON. We identified quantitative thresholds (GCIPL [<65μm] or prior RNFL [<70μm]) at which optic nerve swelling is unlikely to occur during recurrent acute ON. This is important for objective assessment of ON in clinical practice and clinical trials.

Indexed as

Optic AtrophyOptic NerveOptic NeuritisPapilledemaTomography, Optical CoherenceAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedNerve FibersRecurrenceRetinal Ganglion CellsDemyelinating diseaseMultiple sclerosisMyelin oligodendrocyte antibody-associated diseaseOptical coherence tomographyOptic neuritis

Identifiers

PMID42531680
PMCPMC13448249

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.